Inhibition of type 1 diabetes development by vitamin D receptor agonists

Luciano Adorini, Giuseppe Penna, Nadia Giarratana, Roberto Mariani, Milan R. Uskokovic

Research output: Contribution to journalArticle

Abstract

Vitamin D receptor (VDR) agonists are well-known for their capacity to control calcium metabolism and to regulate growth and differentiation of many cell types. More recently, it has become clear that VDR agonists possess exquisite immunoregulatory properties, mostly by targeting dendritic cells and T cells. These properties have been exploited in the treatment of several Th1-mediated experimental autoimmune diseases, and a considerable body of work documents their beneficial effects in inhibiting the development of type 1 diabetes (T1D), a chronic-progressive autoimmune disease leading to the destruction of insulin-producing pancreatic β cells. This review analyzes the capacity of different VDR agonists to inhibit spontaneous T1D development in the non-obese diabetic (NOD) mouse, and shows that 1α,25-(OH)2-16,23Z-diene-26,27-hexafluoro-19-nor D3 (compound 6) is the most effective analog, among those tested, in delaying and reducing disease progression. Identified mechanisms of action underlying the efficacy of this VDR agonist in inhibiting T1D development in the NOD mouse are also reviewed.

Original languageEnglish
Pages (from-to)645-651
Number of pages7
JournalCurrent Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents
Volume4
Issue number6
Publication statusPublished - Dec 2005

    Fingerprint

Keywords

  • Autoimmune diabetes
  • NOD mice
  • Vitamin D analogs

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this